<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2011-7381-285-12262</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Rational dosage schedules of artemisinin based combination treatment for malaria developed in collaboration between Sweden and Uganda</narrative>
   <narrative xml:lang="SV">Rationella doseringsprinciper f&#xF6;r artemisininbaserade kombinationer vid behandling av malaria utvecklade i samarbete mellan Sverige och Uganda</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Idag finns det f&#xE5; effektiva l&#xE4;kemedel f&#xF6;r att bota den allvarliga formen av malaria (falciparum), som d&#xF6;dar omkring 0.9 millioner m&#xE4;nniskor &#xE5;rligen. De flesta &#xE4;r barn i Afrika s&#xF6;der om Sahara. Kombinationsterapi med effektiva kortvarigt verkande artemisininl&#xE4;kemedel (ursprungligen fr&#xE5;n en kinesisk &#xF6;rtmedicin) och l&#xE5;ngvarigt verksamma l&#xE4;kemedel &#xE4;r idag den mest effektiva behandlingen. P&#xE5; senare &#xE5;r har larmrapporter publicerats om att k&#xE4;nsligheten f&#xF6;r artemisiningruppens l&#xE4;kemedel kan vara minskad i Asien. Korrekt dosering av l&#xE4;kemedel mot malaria &#xE4;r d&#xE4;rf&#xF6;r kritiskt f&#xF6;r att bevara effekten av dessa viktiga l&#xE4;kemedel mot malaria. Detta projekt utv&#xE4;rderar om nuvarande rekommenderade doseringsregimer av kombinationsl&#xE4;kemedel med artemisininpreparat &#xE4;r optimala vid behandling av okomplicerad falciparum malaria. Vi studerar fr.a. om intag av lokalt tillg&#xE4;ngliga former av matlagningsolja kan bidra till god och f&#xF6;ruts&#xE4;gbar absorption av lumefantrin, En orsak till minskad k&#xE4;nslighet f&#xF6;r artermisinin kan vara d&#xE5;lig absorption av lumefantrin, som &#xE4;r l&#xE5;ngverkande och eliminerar kvarvarande parasiter efter att artemisinin f&#xF6;rsvunnit ur kroppen. V&#xE5;ra studier kan bidra till att nya doseringsprinciper kan bevara god effekt av de essentiella artemisininl&#xE4;kemedlen f&#xF6;r att behandla malaria. Samarbetet mellan forskare i Uganda och Sverige kan bidra till att st&#xE4;rka kompetensen i principer f&#xF6;r rationell dosering av l&#xE4;kemedel i Afrika. S&#xE5;dan kompetens &#xE4;r v&#xE4;sentlig f&#xF6;r att uppn&#xE5; effektiv och s&#xE4;ker l&#xE4;kemedelsbehandling vid infektionssjukdomar i Afrika. V&#xE5;r forskning bygger p&#xE5; 10 &#xE5;rs samarbete. Vi utnyttjar senaste metodik inom design av kliniska l&#xE4;kemedelsstudier, l&#xE4;kemedelsanalys och vid utv&#xE4;rdering av relationen mellan l&#xE4;kemedelshalt och effekt med matematiska metoder. Vi l&#xE4;gger stor vikt vid att utbilda unga och erfarna forskare genom regelbundna bes&#xF6;k och utbildningar. Merparten av ett beviljat anslag kommer att anv&#xE4;ndas till att bekosta forskarutbytet mellan de b&#xE5;da l&#xE4;nderna.</narrative>
   <narrative xml:lang="EN">Plasmodium falciparum malaria is a public health problem killing 0.9 million people yearly-most of them children in Africa South of Sahara. Artemisinin combination therapy (ACT) of short-acting artermisinin derivatives and long acting compounds are WHO recommended first line therapy. Alarming reports from Asia suggest that the sensitivity of artemisinin compounds in treating malaria may be decreasing. Consequently, correct dosages of ACT:s are critical to preserve the efficacy of these essential antimalarials in Africa. This project reevaluates recommended dosage regimens of ACT:s in treating uncomplicated falciparum malaria in Africa. We focus on improving the pediatric dosages of ACT:s and to investigate if locally available cooking oil may provide predictable absorption of lumefantrine, one of the most used ACT partner drugs. This collaborative project between Uganda and Sweden will strengthen competence in rational drug dosage principles in the two countries. A clinical pharmacology centre on rational drug therapy of infectious diseases including malaria and HIV/AIDS will be established in Uganda. Our collaboration builds on 10 years of joint research and training. We use state of the art methods in clinical drug design, in clinical research, in drug analysis and in concentration-effect modelling. The grant contributes to train junior and senior staff in Uganda and Sweden by frequent short visits to learn from each other and strengthen collaboration.</narrative>
  </description>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">Karolinska Institutet</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2012-01-01" type="2"></activity-date>
  <activity-date iso-date="2014-12-31" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="UG" percentage="100">
   <narrative xml:lang="EN">Uganda</narrative>
  </recipient-country>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12262" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Malaria control</narrative>
  </sector>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2013-01-01"></period-start>
   <period-end iso-date="2013-12-28"></period-end>
   <value currency="USD" value-date="2013-01-01">38383.5902474974</value>
  </budget>
  <budget>
   <period-start iso-date="2014-01-01"></period-start>
   <period-end iso-date="2014-12-28"></period-end>
   <value currency="USD" value-date="2014-01-01">36443.6799370253</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2011-11-15"></transaction-date>
   <value currency="USD" value-date="2011-11-15">115576.6504345682</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2014-01-28"></transaction-date>
   <value currency="USD" value-date="2014-01-28">36443.6799370253</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
